Načítá se...
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
Abstract In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical...
Uloženo v:
Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
BMC
2019-06-01
|
Edice: | Cardiovascular Diabetology |
Témata: | |
On-line přístup: | http://link.springer.com/article/10.1186/s12933-019-0864-7 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|